Novartis at FDPS
As of the edition of 20 October 2026, Novartis is on route B at FDPS (farnesyl pyrophosphate synthase), position 1 of 2,016 on that route, with a score of 0.817.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.817
Biology proven in humans0.88
How much the company cares0.92
Room, and a reason to act now0.67
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Took its own drug far in human testing+0.225
Active at the target or its disease area recently+0.200
Few other companies active at the target+0.128
Trials at the target more often meet than miss their main endpoint+0.083
The company’s own follow-on drug+0.044
Why its own drug stopped0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 19 November 2009.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 31 October 1991.
- Does the company have no approved follow-on drug at this target? Not yet established. As of 10 November 2000.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Zoledronic acid anhydrous | Marketed | Phase 4 | 287 | none listed |
| Pamidronic acid | Marketed | Phase 4 | 26 | none listed |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT00171925 | Zoledronic acid anhydrous | Phase 3 | Terminated | 2000 to 2008 | 143 | No results posted |
| The registry records: “Recruitment in study could not be reached after 8 yrs of recruiting” | ||||||
| NCT00005073 | Zoledronic acid anhydrous | Phase 3 | Terminated | 1999 to 2003 | 544 | No results posted |
| NCT00051636 | Zoledronic acid anhydrous | Phase 3 | Completed | 2001 to 2011 | 172 | No results posted |
| NCT00738257 | Pamidronic acid | Phase 4 | Completed | 2000 | 126 | No results posted |
| NCT00003884 | Zoledronic acid anhydrous | Phase 3 | Completed | 1998 to 2001 | 600 | No results posted |